When was Ideaya Biosciences founded?

Ideaya Biosciences was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Ideaya Biosciences located?

Ideaya Biosciences is headquartered in San Francisco, United States. It is registered at 7000 Shoreline Court, Suite 350 South San Francisco, CA 94080.

Who is the current CEO of Ideaya Biosciences?

Yujiro S H of Ideaya Biosciences.

How many employees does Ideaya Biosciences have?

As of Aug 31, 2026, the latest employee count at Ideaya Biosciences is 282.

Is Ideaya Biosciences a funded company?

Ideaya Biosciences is a funded company, having raised a total of $157M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 03, 2016.

When was the latest funding round of Ideaya Biosciences?

Ideaya Biosciences' latest funding was a $***** Post IPO round on Aug 04, 2020, with participation from 1 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.97B in funding in 2026 to date.

What is the annual revenue of Ideaya Biosciences?

Annual revenue of Ideaya Biosciences is between $100M and $500M as on Dec 31, 2025

Where does Ideaya Biosciences rank among its competitors?

Ideaya Biosciences ranks 4th amongst 3364 active competitors, of which 1128 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Ideaya Biosciences?

Ideaya Biosciences' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Ideaya Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of oncology-focused precision medicine using molecular diagnostics. The lead candidate IDE196 is a protein kinase C an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Others include PARG, WRN, poltheta, Darovasertib, and others.

Website: ideayabio.com
Registered Address: 7000 Shoreline Court, Suite 350 South San Francisco, CA 94080

Key Metrics

Founded Year

2015

Location

San Francisco, United States

Stage

Public

Total Funding

$157M in 4 rounds

Latest Funding Round

Post IPO, Aug 04, 2020, $*****

Investors

Google Ventures & 16 more

Ranked

4^th among 3364 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

282 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3023 more

Exit Details

Public

View Ideaya Biosciences' full profile

Ideaya Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ideaya Biosciences, Inc. CIN: 47-4268251 , United States, Active	Jun 10, 2015	$100M - $500M (As on Dec 31, 2025)	124 (As on Dec 31, 2023)	-

Ideaya Biosciences got listed on May 23, 2019.

Click here to take a look at Ideaya Biosciences's IPO in detail

Ideaya Biosciences has raised a total funding of $157M over 4 rounds. Its first funding round was on May 03, 2016. Its latest funding round was a Post IPO round on Aug 04, 2020 for $*****. 1 investor participated in its latest round. Ideaya Biosciences has 17 institutional investors.

Here is the list of recent funding rounds of Ideaya Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 04, 2020	2708710	Post IPO	6337092	5162125	3684996	1630432
Mar 15, 2018	2627817	Series B	1373171	1430606	1752022	5AM Ventures & 3 more
Aug 25, 2016	3879252	Series A	6033435	6819059	9289965	5AM Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Ideaya Biosciences's funding rounds and investors

The founders of Ideaya Biosciences are Yujiro S H and Jeff Hager.

Here are the details of Ideaya Biosciences' key team members:

Yujiro S H: CoFounder & CEO of Ideaya Biosciences.
Jeff Hager: Senior Vice President, Head of Biology and Co-Founder of Ideaya Biosciences.

View details of Ideaya Biosciences's Founder profiles and Board Members

Ideaya Biosciences' employee count trend

Ideaya Biosciences has 282 employees as of Aug 26. Here is Ideaya Biosciences's employee count trend over the years:

Employee count trend for Ideaya Biosciences

Uncover Ideaya Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ideaya Biosciences include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Ideaya Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Ideaya Biosciences's competitors? Click here to see the top ones

Ideaya Biosciences has made no investments or acquisitions yet.

Here is the latest report on Ideaya Biosciences's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Ideaya Biosciences

Media has covered Ideaya Biosciences for a total of 33 events in the last 1 year, 20 of them have been about company updates and 2 about partnerships.